BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
Cantor Fitzgerald
Express Scripts
Farmers Insurance

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,846,618

« Back to Dashboard

Which drugs does patent 8,846,618 protect, and when does it expire?

Patent 8,846,618 protects SAXENDA, VICTOZA, and XULTOPHY 100/3.6, and is included in three NDAs. There has been one Paragraph IV challenge on Victoza.

This patent has nine patent family members in nine countries.

Summary for Patent: 8,846,618

Title:Stable formulation of modified GLP-1
Abstract: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.
Inventor(s): Flink; James M. (Klanpenborg, DK), Larsen; Silke Moller (Charlottenlund, DK), Jensen; Simon Bjerregaard (Frederiksberg, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:12/785,861
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncVICTOZAliraglutide recombinantSOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,846,618

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01010Jun 28, 2001
Denmark2001 01011Jun 28, 2001
Denmark2001 01052Jul 4, 2001
Denmark2001 01053Jul 4, 2001
Denmark2002 00093Jan 18, 2002

International Patent Family for Patent: 8,846,618

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1412384► Subscribe
Japan2012051894► Subscribe
Japan5562510► Subscribe
Japan2004535442► Subscribe
Spain2298378► Subscribe
European Patent Office1412384► Subscribe
Denmark1412384► Subscribe
Germany60224284► Subscribe
Australia2002316811► Subscribe
Austria382057► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: